Abstract: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare primarymalignant neoplasmoriginatingfrom peritoneal mesothelial cells.The purpose of this study is to summarize the definition, diagnosis, patient management process, and Milan cytoreductive surgery-hyperthermic intraperitoneal chemoperfusion (CRS-HIPEC) treatment data for DMPM. Furthermore, we examine the prognosis effect of perioperative chemotherapy on DMPMpatients as well as the treatment recommendations for polycystic peritoneal mesothelioma and papillary peritoneal mesothelioma. We also describe theMilan’s understanding of DMPMand experience with its treatment.By studying the clinical and biological characteristics of DMPM, the evidence indicates that resectableDMPM should receive CRS-HIPEC treatment, which may alter the patient’s natural disease course.